[ad_1]
In a letter to the editor published today in the New England Journal of Medicine, researchers studying the Moderna COVID-19 vaccine, mRNA-1273, said that neutralizing antibodies to the virus remained high in all participants 3 months after the booster vaccination.
The vaccine, administered at a dose of 100 μg, was found to produce high levels of binding and neutralizing antibodies which decreased slightly over time.
“On day 119, the geometric mean titer (GMT) was 235228 (95% confidence interval [CI], 177,236 to 312,195) in participants aged 18 to 55, 151761 (95% CI, 88.571 to 260.033) in those 56 to 70 years and 157946 (95% CI, 94345 to 264,420) in those 71 years or older ” , wrote the investigators.
Investigators said that while protection against the virus is still unknown, the Moderna vaccine may provide long-term immunity.
“These results show that despite an expected slight decline in binding and neutralizing antibody titers, mRNA-1273 has the potential to provide long-lasting humoral immunity,” they wrote.
They also said that participants did not experience any serious adverse events during the trial or after day 57.
The Moderna vaccine is a nucleoside-modified messenger RNA (mRNA) platform encoded for a pre-fused stabilized form of the SARS-CoV-2 spike protein.
The company announced earlier this week that it would submit its vaccine to the United States Food and Drug Administration (FDA) for emergency use authorization (EUA). Its meeting is scheduled for December 17 and a potential approval could take place shortly thereafter.
[ad_2]
Source link